Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Prescribing Hope: The Placebo Effect Endures

Philip Seo, MD, MHS  |  Issue: June 2018  |  June 21, 2018

rzstudio / shutterstock.com

rzstudio / shutterstock.com

“Wait. I can explain.”

One could imagine this phrase coming up under many conditions in daily life. When I first became a physician, however, I would never have expected to use this phrase in my clinic.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In medical school, I was taught the importance of dialogue in establishing a relationship with a patient. Statistics indicate physicians allow patients to speak for only a few minutes before being interrupted. This leaves the patient with the impression that he or she has not been heard. For physicians, the process of gathering the history of present illness is pragmatic. It is goal directed. For patients, however, the goal is the process. It is an unburdening, a medical confession of past sins and future worries that needs time, and moments of silence, to be allowed to breathe.

When it comes time to lay out a treatment plan, however, the dialogue transforms into a monologue. “Let me go first,” I say. “Give me a chance to go through everything. Then, when I am finished, you can ask your questions.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

I am sure my clinical skills preceptor would be horrified, but I developed this system after years of watching the horrified expressions on my patient’s faces when they heard what I was recommending. Cytotoxic agents. Repurposed cancer medications. Hemorrhagic cystitis. Progressive multifocal leukoencephalopathy. Anemia. Liver failure. The list goes on.

So I developed a different approach. Wait, I can explain. This is the drug I want to use. These are the awful things you will read about this drug on the Internet. This is why I don’t want you to worry. Like the feedback sandwiches we are taught to deliver to trainees, I try to end on a high note, emphasizing why the bad isn’t all that bad and why the plan is the plan.

I use the same approach when I sell patients on glucosamine and chondroitin sulfate.

Wait. I can explain. I know there are multiple, well-designed, clinical trials demonstrating that glucosamine and chondroitin sulfate don’t work for the treatment of osteoarthritis. They are not disease modifying.

And yet, years ago, I attended a lecture on psoriatic arthritis. I no longer remember the name of the speaker, but he mentioned that not only had he studied psoriatic arthritis, but he was also afflicted with the disease. He also mentioned that he took glucosamine and chondroitin sulfate, and he wanted all of us to stop telling him it didn’t work. Because it did, at least for him, and he was tired of his colleagues telling him otherwise.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:patient communicationpatient managementplacebo

Related Articles

    How to Discuss Anti-Inflammatory Diets & Supplements with Your Patients

    June 9, 2023

    My patients ask me almost daily what kind of diet they should be on, or if there are certain supplements they should try. And a growing amount of evidence shows lifestyle and dietary factors may contribute to disease risk and outcomes in rheumatic disease. Thus, rheumatologists and rheumatology professionals are being called upon by patients…

    Is Acupuncture for Pain a Placebo Treatment?

    November 1, 2010

    An examination of the evidence

    The End of the Beginning: COVID-19 Vaccines & Other Conundrums

    December 9, 2020

    “It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEAfter some fits and starts, I finally struck…

    Space & Other Races

    October 19, 2020

    On April 5, 1950, a small group of scientists met in Silver Spring, Md., to talk about geophysics. I know this is not the most riveting way to start, but if you stick with me, I promise the story will get much more interesting. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEThis group of scientists met to discuss…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences